Aspira Women's Health Inc.0000926617false00009266172026-01-302026-01-30

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  November 16, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

  ​ ​ ​

001-34810

  ​ ​ ​

33-0595156

(State or other jurisdiction of

​

(Commission

​

(IRS Employer

incorporation or organization)

​

File Number)

​

Identification No.)

​

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of each class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Common Stock, par value $0.001

​

AWHL

​

OTC QX Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 4.02

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

​

On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Aspira Women’s Health Inc. (the “Company”), after discussion with management and the Company’s independent registered public accounting firm, concluded that the Company’s previously issued unaudited Condensed Consolidated Financial Statements as of and for the three and six months ended March 31, and June 30, 2026 (the “Affected Periods”) included in the Company’s Quarterly Reports on Form 10-Q filed on May 15, 2026, and August 14, 2026, should no longer be relied upon due to material errors in the unaudited Condensed Consolidated Statement of Cash Flows.

​

During the preparation of its financial statements for the period ended September 30, 2026, management identified errors in the presentation and classification of certain loan proceeds and related payments under Accounting Standards Codification (“ASC”) Topic 230, Statement of Cash Flows. Specifically, the restatement reflects the correction of the recording of a loan obtained in January 2026 and related payments that were previously reported within operating activities in the Statement of Cash Flows rather than financing activities.  

 

These restatement adjustments had no impact on the Company’s previously reported unaudited Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations or total net change in cash, cash equivalents, and restricted cash for the Affected Periods.  

 

The following table presents the impact of the restatement on the Company’s unaudited Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2026 (in thousands): 

 

​

​

​

​

Statement of Cash Flows – Three Months ended March 31, 2026 

As Previously Reported  

Restatement Adjustments 

As Restated 

Cash Flows from Operating Activities   

​

​

​

Amortization of debt issuance costs  

 $              -    

 $             15  

 $             15  

Other liabilities   

 $       1,380  

 $          (775) 

 $            605  

Net cash used in operating activities 

 $        (359) 

 $          (760) 

 $      (1,119) 

​

​

​

​

Cash Flows from Financing Activities   

​

​

​

Proceeds from Jan. 2026 Agile Loan  

 $              -    

 $         1,050  

 $         1,050  

Principal repayments of Jan. 2026 Agile loan  

 $              -    

 $          (240) 

 $         (240) 

Payment of debt issuance costs  

 $              -    

 $            (50) 

 $           (50) 

Net cash provided by financing activities 

 $         (52) 

 $           760 

 $            708 

​

​

The following table presents the impact of the restatement on the Company’s unaudited Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2026 (in thousands): 

​

​

​

​

​

Statement of Cash Flows – Six Months ended June 30, 2026 

As Previously Reported  

Restatement Adjustments 

As Restated 

Cash Flows from Operating Activities  

  ​

  ​

  ​

Amortization of debt issuance costs  

 $              -    

 $             37  

 $             37  

Other liabilities   

 $            53  

 $          (345) 

 $         (292) 

Net cash used in operating activities 

 $     (2,369) 

 $          (308) 

 $      (2,677) 

​

​

​

​

Cash Flows from Financing Activities   

  ​

  ​

  ​

Proceeds from Jan. 2026 Agile Loan  

 $              -    

 $         1,050  

 $         1,050  

Principal repayments of Jan. 2026 Agile loan  

 $              -    

 $          (692) 

 $         (692) 

Payment of debt issuance costs  

 $              -    

 $            (50) 

 $           (50) 

Net cash provided by financing activities 

 $       1,241 

 $           308 

 $         1,549 

​

​

The Company plans to restate the unaudited Condensed Consolidated Financial Statements contained in the Company’s Quarterly Reports on Form 10-Q for the three months ended March 31, 2026 and the six months ended June 30, 2026. 

​

The Company’s management evaluated its prior conclusions regarding the effectiveness of the Company’s disclosure controls and procedures and internal control over financial reporting. Based on that evaluation, management has concluded that this matter resulted in a material weakness in the Company’s internal control over financial reporting, which will be disclosed in Item 9A of the Form 10-Q/A. As a result of the material weakness, the Company has concluded that its internal control over financial reporting and its disclosure controls and procedures were ineffective as of the periods referenced above. The Company is taking steps to enhance its procedures and controls surrounding the accounting for significant, non-routine or complex transactions and will continue to refine these procedures and controls. The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient time and management has concluded, through testing, that these controls are operating effectively.

​

The Audit Committee has discussed with BDO USA, P.C., the Company’s independent registered public accounting firm, matters disclosed in this Item 4.02 Form 8-K.

​

​

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 16, 2026

​

 

ASPIRA WOMEN’S HEALTH INC.

 

 

 

 

By:

/s/ John Strahley

 

Name: 

John Strahley

 

Title:

Chief Financial Officer

​


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-101.SCH

EX-101.LAB

EX-101.PRE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: awhl-20261113x8k_htm.xml